Yes, significant late-stage clinical data for Alzheimer’s treatment candidates is expected throughout 2026. As of early 2026, at least four major Phase 3 trials are scheduled to report results between March and June, and a fifth drug candidate is awaiting FDA decision on a key indication. The Alzheimer’s treatment landscape has expanded dramatically, with 182 clinical trials now assessing 138 different candidate treatments—an increase of 18 trials testing 11 new agents since January 2024 alone.
This article covers the most consequential trials expected to deliver data this year, the composition of the broader pipeline, and what these results could mean for people living with Alzheimer’s disease and their families. The growing pipeline reflects decades of increased investment in Alzheimer’s research and a shift from trial-and-error to mechanism-targeted approaches. Instead of waiting months to hear about new therapies in the news, you can anticipate specific readout dates and understand what each trial is measuring.
Table of Contents
- What Are Phase 3 Trials and Why Do Their Results Matter for Alzheimer’s?
- The Alzheimer’s Pipeline Has Expanded Significantly Since 2024
- Four Major Phase 3 Trials Are Delivering Results in 2026
- Different Therapeutic Approaches Are Being Tested Simultaneously
- Recent Clinical Data and Imminent FDA Decisions Point to More Options in 2026
- Medical Devices Represent an Emerging Category in Alzheimer’s Research
- What 2026 Results Mean for the Alzheimer’s Treatment Landscape
- Conclusion
What Are Phase 3 Trials and Why Do Their Results Matter for Alzheimer’s?
Phase 3 trials represent the final major testing phase before a drug can be submitted to the FDA for approval. These are large, randomized controlled studies—often involving over 1,000 participants—that test whether a treatment actually works as intended in diverse patient populations. For Alzheimer’s, Phase 3 trials typically measure cognitive decline using standardized assessments (like the ADAS-cog or MMSE) or objective biomarkers like amyloid plaque clearance on PET scans. The reason Phase 3 data matters so much is simple: it’s the last definitive test before a drug enters the market.
Unlike earlier trial phases that establish safety in smaller groups, Phase 3 results tell us whether benefits observed in Phase 1 and Phase 2 hold up when thousands of patients receive the drug. A therapy might show promise in 100 people but fail to replicate that benefit in 1,600. Conversely, a modest benefit seen in hundreds can become statistically robust and clinically meaningful in larger populations. For families facing Alzheimer’s diagnosis, Phase 3 results directly determine which new treatment options will actually become available to them.
The Alzheimer’s Pipeline Has Expanded Significantly Since 2024
The composition of the current pipeline reveals an important shift in research strategy. Of the 138 candidate treatments now in development, roughly 43 percent are small molecule drugs (pills or injectables like traditional pharmaceuticals), 30 percent target biological disease mechanisms directly, 14 percent focus on cognitive enhancement, and 11 percent address neuropsychiatric symptoms like agitation or depression. This diversity matters because a person with early-stage Alzheimer’s might benefit most from a disease-targeting agent, while someone in later stages with behavioral symptoms might gain more from a neuropsychiatric treatment.
However, the growth from 127 to 138 candidates over 14 months also highlights a critical limitation: not all of these will succeed. Historical data on Alzheimer’s drug development shows a high failure rate, particularly when Phase 2 results don’t translate to Phase 3. The 56 new trials added since January 2024 (including 10 new Phase 3 studies, 25 Phase 2 studies, and 21 Phase 1 studies) represent increased confidence from researchers and sponsors, but they also reflect the reality that many candidates will be discontinued along the way. Success in one trial does not guarantee success in another population or formulation.
Four Major Phase 3 Trials Are Delivering Results in 2026
Eli Lilly’s Remternetug is scheduled to complete enrollment and data collection for the TRAILRUNNER-ALZ 1 trial by March 2026. This Phase 3 study involves over 1,600 participants and tests both an intravenous formulation and an injectable version against placebo, measuring amyloid-beta plaque clearance on brain imaging as the primary endpoint. A March completion means readout could occur in late spring or early summer 2026. The dual formulation aspect is significant because it addresses a practical concern: if intravenous dosing requires frequent clinic visits, patients and caregivers might prefer an injectable version administered at home or less frequently.
Biogen’s BIIB080 (CELIA trial) focuses on tau, a different protein implicated in Alzheimer’s pathology. The trial was fully enrolled as of April 2025 and is expected to complete by May 2026. Tau-targeting therapies represent a distinct mechanistic approach from the amyloid-focused drugs that recently received FDA approval, and a positive result would expand treatment options for patients who might not tolerate or benefit from amyloid-directed therapy. AriBio’s AR1001 trial involves over 1,500 participants with results anticipated in the latter half of 2026, while Cognito Therapeutics’ SPECTRIS headset trial—a medical device using flickering lights and sounds to stimulate brain activity—will report on 670 participants with expected completion in June 2026. The SPECTRIS trial is noteworthy because it represents a non-pharmacological approach; if successful, it would offer an alternative or adjunctive option for people unable or unwilling to use medications.
Different Therapeutic Approaches Are Being Tested Simultaneously
The diversity of mechanisms being tested reflects competing hypotheses about Alzheimer’s causes and progression. Amyloid-targeted therapies (like the approved drugs Leqembi and Kisunla) assume that clearing amyloid plaques will slow decline, particularly early in disease. Tau-targeting agents like BIIB080 address a different pathology that predominates later in the disease course. Cognitive enhancers and neuropsychiatric agents tackle symptoms rather than underlying pathology.
A practical limitation is that a breakthrough in one mechanism doesn’t necessarily mean all approaches in that category will succeed. For example, amyloid-targeting has shown clinical benefit in early Alzheimer’s, but it hasn’t eliminated cognitive decline—it has slowed it. Similarly, tau-targeted therapies in development may prove effective for certain patient subgroups (those at specific disease stages or with particular biomarker profiles) but not others. Patients and caregivers should expect that 2026 results will likely show which mechanisms work in which populations, not a single “cure” that works for everyone.
Recent Clinical Data and Imminent FDA Decisions Point to More Options in 2026
Anavex’s Blarcamesine showed encouraging results in the AD-004 study, particularly in patients with specific genetic markers who demonstrated greater clinical and structural benefit. Data presented at the AD/PD 2026 Conference included evidence of brain volume preservation—a surrogate measure suggesting the drug may protect against neurodegeneration. Merck presented tau-targeting data for MK-2214 and MK-1167 at CTAD 2025, with MK-2214 receiving FDA Fast Track Designation, a pathway that accelerates review if preliminary data is promising.
The most immediate regulatory milestone is the FDA’s expected decision on Axsome Therapeutics’ AXS-05 for Alzheimer’s-related agitation by April 30, 2026. This approval would mark the first FDA decision of 2026 specifically for Alzheimer’s and would target a symptom—agitation and behavioral disturbance—that significantly affects quality of life for patients and caregivers. Roche’s Trontinemab showed impressive biomarker results in Phase 1/2 (92 percent of patients achieved no measurable amyloid plaques after 28 weeks), but Phase 3 results are expected in 2028, not 2026, making this a longer-term prospect.
Medical Devices Represent an Emerging Category in Alzheimer’s Research
Cognito Therapeutics’ SPECTRIS headset differs fundamentally from drug-based approaches. The device uses sensory stimulation to potentially enhance brain activity and reduce amyloid accumulation. The Phase 3 trial with 670 participants completing in June 2026 will be the first major test of whether this non-pharmaceutical approach meets regulatory and clinical standards.
If successful, it would offer patients an option that avoids medication side effects and requires no systemic drug exposure—an important consideration for people with other health conditions or those taking multiple medications. However, a limitation of device-based therapies is adherence and accessibility. Even if effective, a headset device that requires regular use may have adherence challenges that pills do not, and it may be less accessible in certain care settings. The SPECTRIS results will inform whether device-based interventions should be part of the standard Alzheimer’s treatment toolkit.
What 2026 Results Mean for the Alzheimer’s Treatment Landscape
The convergence of four to five major readouts in 2026 will likely reshape treatment guidelines and clinical practice. If multiple mechanisms show efficacy (amyloid-targeting, tau-targeting, and cognitive enhancement), the field will face a new challenge: determining which patients benefit from which treatments and whether combination therapy might be necessary. Currently, Leqembi and Kisunla represent the only approved disease-modifying treatments, and both target amyloid in early-stage disease.
results could expand the pipeline to include mid-stage disease treatment options, tau-targeted agents, and potentially device-based interventions. The regulatory and clinical decisions made on the basis of this data will influence research priorities and investment in the years ahead. A setback for one mechanism would redirect investment toward others; breakthroughs could accelerate further trials in that direction. For people living with Alzheimer’s and their families, more treatment options mean more individualized approaches and potentially better outcomes.
Conclusion
Late-stage clinical data expected in 2026 represents a critical inflection point for Alzheimer’s treatment development. Four Phase 3 trials scheduled for completion between March and June 2026, combined with the FDA’s anticipated decision on AXS-05 for agitation, will provide the most comprehensive dataset on next-generation Alzheimer’s therapies since Leqembi’s approval.
The expanded pipeline of 182 trials assessing 138 treatments demonstrates sustained momentum in research, even though many candidates will ultimately fail. For caregivers and patients evaluating current treatment options or considering trial participation, these upcoming readouts offer concrete timelines for when new evidence will be available. Discussions with healthcare providers about whether participation in a Phase 3 trial might be appropriate, or monitoring FDA announcements in spring and early summer 2026, will help ensure families stay informed about emerging options tailored to their specific situation and disease stage.
